Mirtazapine

Remeron, Remeron SolTab, Mirataz

Antidepressant • Noradrenergic and specific serotonergic antidepressant (NaSSA)

Premium

SerotoninergicCNS Depressant

Half-life

20-40 hours

Protein Binding

85%

Metabolized By

CYP1A2, CYP2D6, CYP3A4

External

Drugs.com

Boxed warning

Suicidality in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Blocks presynaptic alpha-2 receptors and 5-HT2/5-HT3 receptors; also H1 antagonist

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·RETT Syndrome With Proven MECP2 Mutation
·Advanced Cancer
·Anorexia
·Weight Loss
·Insomnia

Interactions

1 curated · 1 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
tramadol	major	Risk of serotonin syndrome; mirtazapine lowers seizure threshold

Common adverse effects

Sedation
Increased appetite
Weight gain
Dry mouth
Constipation

Food, alcohol & herbal

Alcohol · major

Severe sedation and impairment

Herbal

St. John's Wort (major) — Risk of serotonin syndrome

Pharmacokinetics

Half-life: 20-40 hours
Protein binding: 85%
Metabolised by: CYP1A2, CYP2D6, CYP3A4

Pregnancy & lactation

Not recorded for Mirtazapine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement

Mirtazapine

Remeron, Remeron SolTab, Mirataz

Antidepressant • Noradrenergic and specific serotonergic antidepressant (NaSSA)

Premium

SerotoninergicCNS Depressant

Half-life

20-40 hours

Protein Binding

85%

Metabolized By

CYP1A2, CYP2D6, CYP3A4

External

Drugs.com

Boxed warning

Suicidality in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Blocks presynaptic alpha-2 receptors and 5-HT2/5-HT3 receptors; also H1 antagonist

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·RETT Syndrome With Proven MECP2 Mutation
·Advanced Cancer
·Anorexia
·Weight Loss
·Insomnia

Interactions

1 curated · 1 major or contraindicated · select a row for management

Interacting drug	Severity	Effect
tramadol	major	Risk of serotonin syndrome; mirtazapine lowers seizure threshold

Common adverse effects

Sedation
Increased appetite
Weight gain
Dry mouth
Constipation

Food, alcohol & herbal

Alcohol · major

Severe sedation and impairment

Herbal

St. John's Wort (major) — Risk of serotonin syndrome

Pharmacokinetics

Half-life: 20-40 hours
Protein binding: 85%
Metabolised by: CYP1A2, CYP2D6, CYP3A4

Pregnancy & lactation

Not recorded for Mirtazapine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, curated interaction pairs.

Not a substitute for clinical judgement

Mirtazapine Drug Profile | PharmaGraphX